MARC details
000 -LEADER |
fixed length control field |
05764cam a2200637Mi 4500 |
001 - CONTROL NUMBER |
control field |
ocn794328376 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
OCoLC |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20221128211740.0 |
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS--GENERAL INFORMATION |
fixed length control field |
m d |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
fixed length control field |
cr |n|---||||| |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
120528s2012 si ob 001 0 eng d |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
EBLCP |
019 ## - |
-- |
793804672 |
-- |
794902679 |
-- |
797852507 |
-- |
817084766 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
9789814317467 |
Qualifying information |
(electronic bk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
9814317462 |
Qualifying information |
(electronic bk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
1280669225 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
9781280669224 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
Cancelled/invalid ISBN |
9789814317450 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
Cancelled/invalid ISBN |
9814317454 |
035 ## - SYSTEM CONTROL NUMBER |
System control number |
(OCoLC)794328376 |
Canceled/invalid control number |
(OCoLC)793804672 |
-- |
(OCoLC)794902679 |
-- |
(OCoLC)797852507 |
-- |
(OCoLC)817084766 |
043 ## - GEOGRAPHIC AREA CODE |
Geographic area code |
n-cn--- |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MED |
Subject category code subdivision |
071000 |
Source |
bisacsh |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
TEC |
Subject category code subdivision |
010010 |
Source |
bisacsh |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MMG |
Source |
bicssc |
049 ## - LOCAL HOLDINGS (OCLC) |
Holding library |
MAIN |
100 1# - MAIN ENTRY--PERSONAL NAME |
Personal author |
Killeen, Matthew J. |
245 10 - TITLE STATEMENT |
Title |
Cardiac Drug Safety |
Medium |
[electronic resource] : |
Subtitle |
a Bench to Bedside Approach. |
260 ## - PUBLICATION INFORMATION |
Place of publication |
Singapore : |
Publisher |
World Scientific, |
Date |
2012. |
300 ## - PHYSICAL DESCRIPTION |
Physical description |
1 online resource (189 pages) |
336 ## - CONTENT TYPE |
Content type term |
text |
Content type code |
txt |
Source |
rdacontent |
337 ## - MEDIA TYPE |
Media type term |
computer |
Media type code |
c |
Source |
rdamedia |
338 ## - CARRIER TYPE |
Carrier type term |
online resource |
Carrier type code |
cr |
Source |
rdacarrier |
505 0# - CONTENTS |
Contents |
Foreword; "Et causae quoque aestimatio saepe morbum solvit"* [Celsus: Prooemium 69, De Medicina]; Preface; Chapter 1 Challenges Facing the Pharmaceutical Industry in the 21st Century; Introduction; The Impact of Cardiac Toxicity on the Pharmaceutical Industry; References; Chapter 2 The Cellular Basis of Cardiac Electrophysiology; Introduction; The Initiation of the Heart Beat; The Ventricular Cardiac Action Potential; The Relationship Between the Cardiac Action Potential and the Electrocardiogram; Ion Channels Underlying the Cardiac Action Potential; Sodium channels. |
505 8# - CONTENTS |
Contents |
Calcium channelsPotassium channels; Cardiac potassium channels; The transient outward potassium channel; Delayed rectifier potassium channels; The ultra rapid delayed rectifier potassium channel; The HERG potassium channel; The slowly activating delayed rectifier potassium channel; Inwardly rectifying potassium channels; Species-dependent variability of potassium channels; Potassium channel subunits; Summary; References; Chapter 3 Clinical Arrhythmia Syndromes; Introduction; The Long QT Syndrome; Congenital Long QT Syndrome; Drug-Induced QT Prolongation; Summary; References. |
505 8# - CONTENTS |
Contents |
Chapter 4 The Mechanisms Underlying Cardiac ArrhythmiasIntroduction; Mechanisms Underlying Cardiac Arrhythmias; Abnormal Automaticity; Early and Delayed Afterdepolarizations; Re-entry; Transmural Dispersion of Repolarization; How does Action Potential and QT Prolongation Generate Arrhythmias?; Does the M-Cell Play a Role in Arrhythmia Induction in Humans?; Using Mouse Models to Study Arrhythmia Mechanisms; Experimental Studies Exploring the Relationship Between Changes in Transmural Repolarization Gradients and Arrhythmias in Mouse Hearts. |
505 8# - CONTENTS |
Contents |
Arrhythmia Mechanisms and Novel Antiarrhythmic Approaches Identified Using the Hypokalemic Mouse ModelSummary; References; Chapter 5 The Mechanisms Underlying Drug-Induced Arrhythmias; Introduction; The Classical Model of Drug-Induced QT Prolongation and Proarrhythmia: HERG Blockade; Additional Mechanisms Contributing to Drug-Induced Arrhythmias; Drug-Induction Activation of Depolarizing Ion Channels; Drug-Induced Changes in Ion Channel Expression; Drug-Induced Sodium Channel Dysfunction; Summary; References; Chapter 6 Assessing Cardiac Safety in Drug Development; Introduction. |
505 8# - CONTENTS |
Contents |
Preclinical Evaluation of Cardiac Drug SafetyThe ICH S7B Guidelines; Single Cell Safety Studies; The Purkinje Fiber Model; The Ventricular Wedge Model; Isolated Heart Models; In Vivo Models; The Impact of Species-Related Differences in Cardiac Electrophysiology on Preclinical Drug Safety Assessment; Methods to Provoke Arrhythmias in Preclinical Studies; Programmed electrical stimulation; Reductions in the extracellular K+ concentration; Clinical Evaluation of Cardiac Safety; The Thorough QT study; Thorough QT study design; Additional Biomarkers to Detect Drug-Induced Proarrhythmia. |
500 ## - GENERAL NOTE |
General note |
Variability of repolarization. |
520 ## - ABSTRACT |
Abstract |
Ensuring the safety of new medical products remains a major challenge for the pharmaceutical industry. Cardiac safety, particularly drug-induced heart rhythm abnormalities, remains an important cause of pipeline attrition and has resulted in countless major product recalls or label changes. The risk of encountering this major adverse event continues to shape the drug development and regulatory landscape. Extensive research over the past decade has shed light on the root causes of arrhythmias that are triggered by medications and has helped drive, and optimize, drug safety testing. However, curr. |
504 ## - BIBLIOGRAPHY, ETC. NOTE |
Bibliography, etc |
Includes bibliographical references and index. |
650 #0 - SUBJECT HEADINGS |
Subject term |
Arrhythmia |
General subdivision |
Treatment. |
650 #0 - SUBJECT HEADINGS |
Subject term |
Drugs |
General subdivision |
Safety regulations |
Geographic subdivision |
Canada. |
650 #2 - SUBJECT HEADINGS |
Subject term |
Heart |
General subdivision |
drug effects. |
650 #2 - SUBJECT HEADINGS |
Subject term |
Drug Toxicity |
General subdivision |
prevention & control. |
856 40 - ONLINE RESOURCE |
Uniform Resource Identifier |
<a href="https://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=457178">https://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=457178</a> |
Link text |
Kingston Hospital NHS Foundation Trust OpenAthens account holders click here for access |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Suppress in OPAC |
Do not Suppress in OPAC |
588 0# - SOURCE OF DESCRIPTION NOTE |
Source of description note |
Print version record. |
938 ## - |
-- |
123Library |
-- |
123L |
-- |
114800 |
938 ## - |
-- |
Coutts Information Services |
-- |
COUT |
-- |
23981151 |
938 ## - |
-- |
EBL - Ebook Library |
-- |
EBLB |
-- |
EBL919080 |
938 ## - |
-- |
ebrary |
-- |
EBRY |
-- |
ebr10563572 |
938 ## - |
-- |
EBSCOhost |
-- |
EBSC |
-- |
457178 |
938 ## - |
-- |
Ingram Digital eBook Collection |
-- |
IDEB |
-- |
364615 |
938 ## - |
-- |
YBP Library Services |
-- |
YANK |
-- |
7280427 |
994 ## - |
-- |
92 |
-- |
N$T |